241 related articles for article (PubMed ID: 12184410)
1. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
[TBL] [Abstract][Full Text] [Related]
2. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
3. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
4. Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Urology; 2002 Jul; 60(1):98-103. PubMed ID: 12100932
[TBL] [Abstract][Full Text] [Related]
5. Five-year biochemical outcome after prostate brachytherapy for hormone-naive men < or = 62 years of age.
Merrick GS; Butler WM; Lief JH; Galbreath RW
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1253-7. PubMed ID: 11483336
[TBL] [Abstract][Full Text] [Related]
6. Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation.
Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
Brachytherapy; 2002; 1(2):95-101. PubMed ID: 15062177
[TBL] [Abstract][Full Text] [Related]
7. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
[TBL] [Abstract][Full Text] [Related]
8. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
[TBL] [Abstract][Full Text] [Related]
9. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
[TBL] [Abstract][Full Text] [Related]
10. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
[TBL] [Abstract][Full Text] [Related]
11. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
12. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external-beam radiation.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Cancer J; 2004; 10(1):54-60. PubMed ID: 15000496
[TBL] [Abstract][Full Text] [Related]
14. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
Ellis RJ; Vertocnik A; Kim E; Zhou H; Young B; Sodee B; Fu P; Beddar S; Colussi V; Spirnak JP; Dinchman KH; Resnick M; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):362-70. PubMed ID: 12957246
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
16. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
17. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
Cancer J; 2005; 11(3):234-40. PubMed ID: 16053667
[TBL] [Abstract][Full Text] [Related]
18. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
Am J Clin Oncol; 2004 Dec; 27(6):611-5. PubMed ID: 15577440
[TBL] [Abstract][Full Text] [Related]
19. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
20. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]